![](/img/cover-not-exists.png)
ATIM-24. TARGETING MYELOID DERIVED SUPPRESSOR CELLS: PHASE 0/1 TRIAL OF LOW DOSE CAPECITABINE + BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA
Peereboom, David M, Vogelbaum, Michael, Mohammadi, Alireza, Alban, Tyler, Brewer, Cathy, Ahluwalia, Manmeet, Sinyuk, Maksim, Lathia, JustinVolume:
19
Journal:
Neuro-Oncology
DOI:
10.1093/neuonc/nox168.119
Date:
November, 2017
File:
PDF, 88 KB
2017